首页> 外文期刊>Bone >Improvement of the skeletal and dental hypophosphatasia phenotype in Alpl(-/-) mice by administration of soluble (non-targeted) chimeric alkaline phosphatase
【24h】

Improvement of the skeletal and dental hypophosphatasia phenotype in Alpl(-/-) mice by administration of soluble (non-targeted) chimeric alkaline phosphatase

机译:通过使用可溶性(非靶向)嵌合碱性磷酸酶改善Alpl(-/-)小鼠的骨骼和牙齿低磷性表型

获取原文
获取原文并翻译 | 示例
           

摘要

Hypophosphatasia (HFP) results from ALPL gene mutations, which lead to a deficiency of tissue-nonspecific alkaline phosphatase (TNAP), and accumulation of inorganic pyrophosphate, a potent inhibitor of mineralization that is also a natural substrate of TNAP, in the extracellular space. HPP causes mineralization disorders including soft bones (rickets or osteomalacia) and defects in teeth and periodontal tissues. Enzyme replacement therapy using mineral-targeting recombinant TNAP has proven effective in preventing skeletal and dental defects in TNAP knockout (Alpl(-/-)) mice, a model for life-threatening HPP. Here, we show that the administration of a soluble, intestinal-like chimeric alkaline phosphatase (ChimAP) improves the manifestations of HPP in Alpl(-/-) mice. Mice received daily subcutaneous injections of ChimAP at doses of 1, 8 or 16 mg/kg, from birth for up to 53 days. Lifespan and body weight of Alpl(-/-) mice were normalized, and vitamin B6-associated seizures were absent with 16 mg/kg/day of ChimAP. Radiographs, mu CT and histological analyses documented improved mineralization in cortical and trabecular bone and secondary ossification centers in long bones of ChimAP16-treated mice. There was no evidence of craniosynostosis in the ChimAP16-treated mice and we did not detect ectopic calcification by radiography and histology in the aortas, stomachs, kidneys or lungs in any of the treatment groups. Molar tooth development and function improved with the highest ChimAP dose, including enamel, dentin, and tooth morphology. Cementum remained deficient and alveolar bone mineralization was reduced compared to controls, though ChimAP-treated Alpl(-/-) mice featured periodontal attachment and retained teeth. This study provides the first evidence for the pharmacological efficacy of ChimAP for use in the treatment of skeletal and dental manifestations of HPP. (C) 2014 Elsevier Inc. All rights reserved.
机译:低磷症(HFP)是由ALPL基因突变引起的,该突变导致组织非特异性碱性磷酸酶(TNAP)的缺乏,以及无机焦磷酸盐(一种有效的矿化抑制剂,也是TNAP的天然底物)在细胞外空间的积累。 HPP会导致矿化障碍,包括软骨头(rick病或骨软化症)以及牙齿和牙周组织的缺陷。已证明使用靶向矿物质的重组TNAP的酶替代疗法可有效预防TNAP基因敲除(Alpl(-/-))小鼠的骨骼和牙齿缺陷,该模型可威胁生命。在这里,我们显示了可溶性,肠样嵌合碱性磷酸酶(ChimAP)的管理改善了Alpl(-/-)小鼠中HPP的表现。小鼠从出生起每天接受皮下注射ChimAP的剂量分别为1、8或16 mg / kg,最多持续53天。将Alpl(-/-)小鼠的寿命和体重恢复正常,并且每天16 mg / kg /天的ChimAP不存在维生素B6相关的癫痫发作。射线照片,mu CT和组织学分析表明,使用ChimAP16治疗的小鼠的皮质和小梁骨以及长骨的次生骨化中心矿化得到改善。没有经过ChimAP16治疗的小鼠颅骨前突的证据,在任何治疗组中,我们都没有通过放射学和组织学方法在主动脉,胃,肾或肺中检测到异位钙化。使用最高的ChimAP剂量(包括牙釉质,牙本质和牙齿形态)可以改善磨牙的牙齿发育和功能。与ChimAP治疗的Alpl(-/-)小鼠相比,牙骨质仍缺乏,牙槽骨矿化程度降低,但牙周附着并保留了牙齿。这项研究为ChimAP用于治疗HPP骨骼和牙齿表现的药理功效提供了第一个证据。 (C)2014 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号